Metastatic prostate carcinoma

Summary

Metastatic prostate carcinoma (MONDO:0004956) is a cancer and 372 clinical trials. Top therapeutic interventions include cabazitaxel, abiraterone acetate, and apalutamide. A subtype of prostate carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 372

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	metastatic prostate carcinoma
Mondo ID	MONDO:0004956
EFO	EFO:0000196
NCIT	C8946
SNOMED CT	314994000
UMLS	C0936223
MedGen	215232
Is cancer (heuristic)	yes

Also known as: metastatic prostate cancer · metastatic prostate carcinoma · prostate cancer metastatic · prostate carcinoma metastatic

Disease family

This is a subtype of prostate carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › prostate carcinoma › metastatic prostate carcinoma

Related subtypes (8): prostate squamous cell carcinoma, primary prostate urothelial carcinoma, prostate adenocarcinoma, grade III prostatic intraepithelial neoplasia, prostate small cell carcinoma, familial prostate carcinoma, hormone-resistant prostate carcinoma, castration-resistant prostate carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

8 approved, 27 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Abiraterone Acetate	Approved (phase 4)
Apalutamide	Approved (phase 4)
Cabazitaxel	Approved (phase 4)
Darolutamide	Approved (phase 4)
Enzalutamide	Approved (phase 4)
Flutamide	Approved (phase 4)
Nilutamide	Approved (phase 4)
Relugolix	Approved (phase 4)
Abiraterone	Phase 3 (in late-stage trials)
Atezolizumab	Phase 3 (in late-stage trials)
Atorvastatin	Phase 3 (in late-stage trials)
Bevacizumab	Phase 3 (in late-stage trials)
Bicalutamide	Phase 3 (in late-stage trials)
Creatine	Phase 3 (in late-stage trials)
Dasatinib Anhydrous	Phase 3 (in late-stage trials)
Degarelix	Phase 3 (in late-stage trials)
Dexamethasone	Phase 3 (in late-stage trials)
Estramustine	Phase 3 (in late-stage trials)
Fludrocortisone Acetate	Phase 3 (in late-stage trials)
Goserelin	Phase 3 (in late-stage trials)
Histrelin	Phase 3 (in late-stage trials)
Hydrocortisone	Phase 3 (in late-stage trials)
Ipatasertib	Phase 3 (in late-stage trials)
Leuprolide	Phase 3 (in late-stage trials)
Mitoxantrone	Phase 3 (in late-stage trials)
Olaparib	Phase 3 (in late-stage trials)
Opevesostat	Phase 3 (in late-stage trials)
Pembrolizumab	Phase 3 (in late-stage trials)
Prednisolone	Phase 3 (in late-stage trials)
Prednisone	Phase 3 (in late-stage trials)
Risedronic Acid	Phase 3 (in late-stage trials)
Sipuleucel-T	Phase 3 (in late-stage trials)
Sunitinib	Phase 3 (in late-stage trials)
Tasquinimod	Phase 3 (in late-stage trials)
Triptorelin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): ANTINEOPLASTON A10, Ascorbic Acid, Carboplatin, Cediranib, Cisplatin, Erdafitinib, Ethylenediamine, Filgrastim, Gozetotide, Indomethacin, Ipilimumab, Lenalidomide, Metformin, Methylprednisolone, Niclosamide, Niraparib, Nivolumab, Pamiparib, Pegfilgrastim, Rezvilutamide, Samarium, Sorafenib, Talazoparib, Testosterone, Testosterone Cypionate, Testosterone Enanthate, Tislelizumab, Trametinib, Zimberelimab.

Clinical trials & evidence

Clinical trials

Clinical trials: 372.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	124
Not specified	103
PHASE1	50
PHASE1/PHASE2	42
PHASE3	31
PHASE4	11
EARLY_PHASE1	8
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03016741	PHASE4	ACTIVE_NOT_RECRUITING	Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
NCT06479187	PHASE4	ACTIVE_NOT_RECRUITING	PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
NCT06706921	PHASE4	RECRUITING	18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
NCT07252726	PHASE4	RECRUITING	Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
NCT00255268	PHASE4	WITHDRAWN	CMAB vs IMAB in Metastatic Prostate Cancer
NCT01933022	PHASE4	TERMINATED	A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
NCT02074137	PHASE4	COMPLETED	Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
NCT02485691	PHASE4	COMPLETED	Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
NCT03432949	PHASE4	UNKNOWN	Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC
NCT04134208	PHASE4	TERMINATED	An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
NCT04776889	PHASE4	COMPLETED	The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients
NCT01957436	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT02051218	PHASE3	ACTIVE_NOT_RECRUITING	Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
NCT04423211	PHASE3	RECRUITING	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04446117	PHASE3	ACTIVE_NOT_RECRUITING	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04787744	PHASE2/PHASE3	RECRUITING	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04916613	PHASE3	RECRUITING	ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT05352178	PHASE3	RECRUITING	Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05796973	PHASE3	RECRUITING	Measuring Oncological Value of Exercise and Statin
NCT05983783	PHASE3	RECRUITING	Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
NCT06112990	PHASE3	RECRUITING	Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
NCT06136624	PHASE3	RECRUITING	Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06177015	PHASE3	RECRUITING	Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
NCT06320067	PHASE3	RECRUITING	A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
NCT06350825	PHASE3	RECRUITING	Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
NCT06439225	PHASE3	RECRUITING	Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
NCT06496581	PHASE3	RECRUITING	Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
NCT00216060	PHASE3	TERMINATED	Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
NCT00942331	PHASE3	COMPLETED	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
NCT01254279	PHASE3	COMPLETED	Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
NCT01322490	PHASE3	COMPLETED	A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
NCT02260817	PHASE3	COMPLETED	Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
NCT02294461	PHASE3	COMPLETED	An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
NCT02961257	PHASE3	COMPLETED	Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
NCT03072238	PHASE3	COMPLETED	Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03295565	PHASE2/PHASE3	COMPLETED	Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
NCT03389451	PHASE2/PHASE3	COMPLETED	68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
NCT03739684	PHASE3	COMPLETED	Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
NCT03850795	PHASE3	TERMINATED	HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT04026230	PHASE3	UNKNOWN	Impact of Atorvastatin on Prostate Cancer Progression During ADT

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABAZITAXEL	4	15
ABIRATERONE ACETATE	4	12
APALUTAMIDE	4	11
DAROLUTAMIDE	4	11
ENZALUTAMIDE	4	11
ABIRATERONE	4	10
GOZETOTIDE	4	10
SIPULEUCEL-T	4	6
DEGARELIX	4	5
GOSERELIN	4	5
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	4	5
PIFLUFOLASTAT F18	4	5
LEUPROLIDE	4	4
TESTOSTERONE CYPIONATE	4	4
DEXAMETHASONE	4	3
FLUCICLOVINE F18	4	3
FLUDEOXYGLUCOSE F 18	4	3
NICLOSAMIDE	4	3
PREDNISONE	4	3
RELUGOLIX	4	3
CABOZANTINIB	4	2
DASATINIB ANHYDROUS	4	2
FLUDROCORTISONE ACETATE	4	2
OLAPARIB	4	2
TESTOSTERONE ENANTHATE	4	2
ATEZOLIZUMAB	4	1
AVELUMAB	4	1
BICALUTAMIDE	4	1
GEMCITABINE HYDROCHLORIDE	4	1
HISTRELIN	4	1